Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $17.28, for a total value of $172,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.10, for a total value of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.25, for a total value of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.75, for a total value of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.02, for a total value of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.44, for a total value of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.67, for a total value of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.76, for a total value of $1,156,051.68.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.06, for a total value of $304,762.50.

Shares of Crispr Therapeutics AG (NASDAQ:CRSP) traded up $0.01 during trading hours on Thursday, hitting $18.53. The company’s stock had a trading volume of 197,500 shares, compared to its average volume of 142,711. Crispr Therapeutics AG has a fifty-two week low of $11.63 and a fifty-two week high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. During the same period in the prior year, the firm posted ($2.77) EPS. The business’s revenue was up 54.2% on a year-over-year basis. equities research analysts forecast that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Granahan Investment Management Inc. MA raised its stake in shares of Crispr Therapeutics by 51.7% during the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after acquiring an additional 89,839 shares in the last quarter. Allianz Asset Management GmbH bought a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $2,384,000. Credit Suisse AG bought a new stake in shares of Crispr Therapeutics during the first quarter valued at approximately $1,742,000. Adams Street Partners LLC bought a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $1,019,000. Finally, Hershey Trust Co. bought a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $768,000. 24.55% of the stock is owned by hedge funds and other institutional investors.

CRSP has been the subject of several recent research reports. Barclays reiterated a “buy” rating and issued a $29.00 price target on shares of Crispr Therapeutics in a research report on Friday, September 8th. SunTrust Banks restated a “hold” rating and set a $16.00 target price on shares of Crispr Therapeutics in a research report on Friday, November 10th. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Chardan Capital restated a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, August 14th. Finally, BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Crispr Therapeutics currently has an average rating of “Hold” and a consensus price target of $22.38.

ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/07/insider-selling-crispr-therapeutics-ag-crsp-major-shareholder-sells-10000-shares-of-stock.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.